All Dr Vincent Blomen (Senior Director of Discovery Sciences at Scenic Biotech) articles

  • Regenerative,Medicine,And,Therapeutic,Stem,Cell,Therapy,To,Regrow,Damaged
    News

    Targeting PLA2G15 to treat neurometabolic disorders

    2025-05-20T08:30:51Z

    Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.